Risk of Depression Associated With Finasteride Treatment

Abstract

Abstract Background Finasteride is one of several inhibitors of the 5α-reductase that converts testosterone to dihydrotestosterone used to treat hair loss and benign prostatic enlargement. Emerging clinical observations indicate that such treatment may be associated with depression, anxiety, and possibly increased suicidal risks, in addition to sexual dysfunction, even after its discontinuation. Methods We carried out a systematic review of reports pertaining to association of finasteride treatment with clinical depression or other adverse psychiatric effects. We analyzed reported risks of depression by pooling of rates and by meta-analysis of comparisons of subjects treated with finasteride or not. Findings Crude pooled rates of depressive symptoms with versus without finasteride were 3.33% (confidence interval, 3.22%–3.44%) versus 2.54% (2.44%–2.64%); random-effects meta-analysis yielded an odds ratio of 2.14 (1.40–3.27) (both P < 0.0001). In addition, risk of suicidal ideation or behavior was greater with versus without finasteride (21.2% [21.0%–21.5%] vs 14.0% [13.8%–14.2%], P < 0.0001), and risk of sustained sexual dysfunction was high (60.1% [37.3%–82.9%]). Conclusions The findings support a growing impression that finasteride is associated with adverse psychiatric effects that can persist in association with sexual dysfunction after discontinuing finasteride treatment.